Stryker Corporation $SYK Position Lowered by Middleton & Co. Inc. MA

Middleton & Co. Inc. MA lessened its position in shares of Stryker Corporation (NYSE:SYK) by 2.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 22,356 shares of the medical technology company’s stock after selling 460 shares during the quarter. Middleton & Co. Inc. MA’s holdings in Stryker were worth $8,845,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. Mid American Wealth Advisory Group Inc. bought a new position in Stryker during the second quarter worth $26,000. Sachetta LLC raised its holdings in shares of Stryker by 58.7% during the second quarter. Sachetta LLC now owns 73 shares of the medical technology company’s stock worth $29,000 after purchasing an additional 27 shares during the period. Ridgewood Investments LLC lifted its position in shares of Stryker by 48.4% in the 2nd quarter. Ridgewood Investments LLC now owns 92 shares of the medical technology company’s stock worth $36,000 after buying an additional 30 shares during the last quarter. Ransom Advisory Ltd acquired a new position in shares of Stryker in the 1st quarter valued at about $37,000. Finally, Solstein Capital LLC acquired a new stake in Stryker during the second quarter worth about $43,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of SYK opened at $357.76 on Thursday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. The firm’s 50 day moving average is $376.08 and its 200-day moving average is $381.07. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The stock has a market capitalization of $136.82 billion, a P/E ratio of 47.39, a P/E/G ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last released its earnings results on Thursday, October 30th. The medical technology company reported $3.19 EPS for the quarter, beating the consensus estimate of $3.13 by $0.06. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business had revenue of $6.06 billion during the quarter, compared to analyst estimates of $6.04 billion. During the same period in the prior year, the business earned $2.87 earnings per share. The business’s quarterly revenue was up 10.2% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Equities research analysts anticipate that Stryker Corporation will post 13.47 EPS for the current fiscal year.

Insider Activity

In related news, insider Viju Menon sold 500 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the sale, the insider owned 12,511 shares in the company, valued at approximately $4,886,921.71. This represents a 3.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.90% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on SYK. Barclays raised their price target on Stryker from $443.00 to $453.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. BTIG Research boosted their price target on shares of Stryker from $408.00 to $410.00 and gave the company a “buy” rating in a report on Friday, October 31st. Rothschild & Co Redburn initiated coverage on shares of Stryker in a research note on Thursday, September 18th. They set a “neutral” rating and a $420.00 target price for the company. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Stryker in a report on Wednesday, October 8th. Finally, Redburn Partners set a $420.00 target price on Stryker in a research report on Thursday, September 18th. Fourteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $433.37.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.